SAN DIEGO (AP) — GlaxoSmithKline PLC will pay $105 million to dozens of states to settle allegations that it unlawfully marketed its asthma drug Advair and the antidepressants Paxil and Wellbutrin.
Under the settlement announced Wednesday, the London-based pharmaceutical also agreed to rules that bar it from paying doctors to promote its products; providing financial incentives that encourage salespeople to market drugs for unapproved uses; marketing drugs using results from inadequate studies or making unapproved claims that a product was “better, more effective, safer or has less serious side effects,” according to a statement from California Attorney General Kamala D. Harris.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.